The New Mexico protocol is a phase I, community-informed model for group psilocybin-assisted therapy for PTSD, developed by researchers at the University of New Mexico. It prioritizes accessibility by using group sessions with peer facilitators and focuses on safety and feasibility rather than proving effectiveness.
The study is pragmatic and open-label. Six cohorts of six participants are planned, including veterans, first responders, and female survivors of sexual violence. Under FDA IND authorization, whole-mushroom psilocybin formulated as chocolate is administered in two dosing sessions, alongside both group and individual therapy.
Primary outcomes are safety and feasibility, with PTSD symptoms tracked using CAPS-5 and PCL-5. I cannot verify 2026 timelines, but the protocol reports funding and regulatory approvals with recruitment planned to begin in May 2026.
For a concise overview of the design and its community engagement approach, see this summary of the New Mexico protocol: New Mexico group psilocybin protocol.
Hope this helps clarify the essentials.